Details for Patent: 8,476,010

Which drugs does patent 8,476,010 protect, and when does it expire?

Patent 8,476,010 protects DIPRIVAN and is included in one NDA.

Protection for DIPRIVAN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one patent family member in one country.

Summary for Patent: 8,476,010

Title:	Propofol formulations with non-reactive container closures
Abstract:	A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
Inventor(s):	Desai; Neil P. (Pacific Palisades, CA), Yang; Andrew (Rosemead, CA), Ci; Sherry Xiaopei (San Marino, CA)
Assignee:	APP Pharmaceuticals LLC (Schaumburg, IL)
Application Number:	10/616,709
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,476,010
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 8,476,010

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Fresenius Kabi Usa	DIPRIVAN	propofol	INJECTABLE;INJECTION	019627-002	Jun 11, 1996	AB	RX	Yes	Yes					Y

International Family Members for US Patent 8,476,010

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2005007131